EX-4.9





 Exhibit 4.9 

Execution Version 

SUPPLEMENTAL INDENTURE 

SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of May 28, 2020, among
Endo Designated Activity Company (formerly known as Endo Limited), a designated activity company incorporated under the laws of Ireland (the “Company”), Endo Finance LLC (formerly known as Endo Finance Co.), a Delaware limited
liability company (“Endo Finance”), Endo Finco Inc., a Delaware corporation (together with the Company and Endo Finance, the “Issuers”), the Guarantors (as defined in the Indenture referred to below) and Wells Fargo
Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”). 
 W I T N E S S E T H 

WHEREAS, the Issuers have heretofore executed and delivered to the Trustee an indenture, dated as of January 27, 2015, as supplemented by
a supplemental indenture, dated as of February 3, 2015, a supplemental indenture, dated as of March 20, 2015, a supplemental indenture, dated as of March 27, 2015, a supplemental indenture, dated as of June 24, 2015, a
supplemental indenture, dated as of July 9, 2015, a supplemental indenture, dated as of September 30, 2015, a supplemental indenture, dated as of January 13, 2016, a supplemental indenture, dated as of April 4, 2016, a
supplemental indenture, dated as of July 13, 2016, a supplemental indenture, dated as of October 18, 2016, a supplemental indenture, dated as of June 23, 2017, a supplemental indenture, dated as of January 3, 2018, a supplemental
indenture, dated as of July 3, 2018, a supplemental indenture, dated as of December 24, 2018, a supplemental indenture, dated as of March 4, 2019, a supplemental indenture, dated as of September 9, 2019, a supplemental indenture,
dated as of November 25, 2019, a supplemental indenture, dated as of December 17, 2019, a supplemental indenture, dated as of January 21, 2020, and a supplemental indenture, dated as of March 31, 2020, in each case, among the
Issuers, the Guarantors party thereto and the Trustee (as so supplemented, the “Indenture”), providing for the issuance of 6.000% Senior Notes due 2025 (the “Notes”); 

WHEREAS, the Issuers have offered to exchange any and all of the outstanding Notes from the registered holders (the
“Holders”) of the Notes for new notes (the “Exchange Offer”) and, in conjunction with the Exchange Offer, have solicited consents from the Holders of the Notes to the amendments to the Indenture contained herein
(the “Consent Solicitation”), in each case, upon the terms and subject to the conditions as set forth in the offering memorandum and consent solicitation statement, dated May 14, 2020, as supplemented on May 28, 2020; 

WHEREAS, Section 9.02 of the Indenture provides that, subject to certain exceptions inapplicable hereto, the
Issuers, the Guarantors and the Trustee may amend or supplement the Indenture with the consent of at least a majority in aggregate principal amount of the outstanding Notes (the “Requisite Consents”); 

WHEREAS, the Issuers have received the Requisite Consents to effect amendments to the Indenture as set forth in Article II hereof (the
“Consented Amendments”), based on reports provided by D.F. King & Co., Inc., as information agent and exchange agent in the Exchange Offer and Consent Solicitation, and have delivered such Requisite Consents to the Trustee;

 WHEREAS, the execution and delivery of this Supplemental Indenture has been duly authorized by the Issuers and the Guarantors and all
conditions and requirements necessary to make this instrument a valid and binding agreement have been duly performed and complied with; 

WHEREAS, pursuant to Section 9.02 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture; 












 WHEREAS, this Supplemental Indenture shall be effective upon its signing by the parties
hereto, but the provisions of Article II and III will become operative (the “Operative Date”) upon the issuance of the applicable series of new notes issued by the Issuers and Par Pharmaceutical, Inc., a New York corporation
(“PPI” and, together with the Issuers, the “Exchange Notes Issuers”), as applicable, (the “Consideration”) in the Exchange Offer in exchange for all Notes validly tendered and not validly withdrawn
and that are accepted for exchange, on the applicable settlement date of the Exchange Offer (the “Settlement Date”); 

WHEREAS, if the Exchange Offer has been terminated or withdrawn, or if upon the final settlement date of the Exchange Offer the Exchange Notes
Issuers have not issued the Consideration in respect of all Notes validly tendered and accepted for exchange, the terms hereof shall not become operative, this Supplemental Indenture shall be deemed automatically terminated and the Indenture will
remain in effect in its current form; 
 WHEREAS, the Issuers and the Guarantors intend to take the position that this Supplemental
Indenture does not result in a material modification of the Notes under the Foreign Account Tax Compliance Act. 
 NOW, THEREFORE, in
consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Issuers, the Guarantors and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of
the Notes as follows: 
 ARTICLE I 

DEFINITIONS 

SECTION 1.01.    DEFINED TERMS. All capitalized terms used but
not defined herein shall have the meanings ascribed to such terms in the Indenture. All definitions in the Indenture shall be read in a manner consistent with the terms of this Supplemental Indenture. 

ARTICLE II 
 CONSENTED
AMENDMENTS 
 SECTION 2.01.    AMENDMENTS TO CERTAIN
COVENANTS OF THE INDENTURE. Subject to Section 4.02 hereof, the following Sections of the Indenture are hereby amended to read as follows and
any and all references to such sections and provisions of the Indenture which are amended, modified, replaced or deleted and any and all obligations thereunder are hereby deleted throughout the Indenture, and such sections and references shall be of
no further force or effect: 
 a)    Section 3.09 of the Indenture is hereby amended and restated in its entirety
as follows: 
 “SECTION 3.09    [INTENTIONALLY OMITTED]” 

b)    Section 4.03 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.03    [INTENTIONALLY OMITTED]” 

c)    Section 4.05 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.05    [INTENTIONALLY OMITTED]” 

d)    Section 4.06 of the Indenture is hereby amended and restated in its entirety as follows: 

  
 2 













 “SECTION 4.06    [INTENTIONALLY OMITTED]” 

e)    Section 4.07 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.07    [INTENTIONALLY OMITTED]” 

f)    Section 4.08 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.08    [INTENTIONALLY OMITTED]” 

g)    Section 4.09 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.09    [INTENTIONALLY OMITTED]” 

h)    Section 4.10 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.10    [INTENTIONALLY OMITTED]” 

i)    Section 4.11 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.11    [INTENTIONALLY OMITTED]” 

j)    Section 4.12 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.12    [INTENTIONALLY OMITTED]” 

k)    Section 4.13 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.13    [INTENTIONALLY OMITTED]” 

l)    Section 4.14 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.14    [INTENTIONALLY OMITTED]” 

m)    Section 4.16 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.16    [INTENTIONALLY OMITTED]” 

n)    Section 4.17 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.17    [INTENTIONALLY OMITTED]” 

o)    Section 4.18 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.18    [INTENTIONALLY OMITTED]” 

p)    Section 4.19 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.19    [INTENTIONALLY OMITTED]” 

q)    Section 4.20 of the Indenture is hereby amended and restated in its entirety as follows: 

  
 3 













 “SECTION 4.20    [INTENTIONALLY OMITTED]” 

r)    Section 4.22 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 4.22    [INTENTIONALLY OMITTED]” 

s)    Section 10.04 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 10.04    [INTENTIONALLY OMITTED]” 

t)    Section 5.01 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 5.01    Merger, Consolidation or Sale of Assets 

The Company shall not: (1) consolidate with or merge with or into another Person (whether or not the Company is the surviving
corporation); or (2) directly or indirectly, sell, assign, transfer, convey, lease or otherwise dispose of all or substantially all of the assets of the Company and the Restricted Subsidiaries taken as a whole, in one or more related
transactions, to another Person, unless: 
  

	 	(a)	 either: 


  

	 	(1)	 the Company is the surviving corporation; or 



 

	 	(2)	 the Person formed by or surviving any such consolidation or merger (if other than the Company) or the Person to
which such sale, assignment, transfer, conveyance, lease or other disposition has been made assumes all the obligations of the Company under the Notes and this Indenture pursuant to agreements reasonably satisfactory to the Trustee; and



  

	 	(b)	 the Company shall have delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each
stating that such consolidation, merger or transfer and such supplemental indenture (if any) comply with this Indenture. 



This Section 5.01 will not apply to any sale, assignment, transfer, conveyance, lease or other disposition of assets between or among the
Company and the Restricted Subsidiaries. 
 The Person formed by or surviving any such consolidation or merger (if other than the Company) or
the Person to which such sale, assignment, transfer, conveyance, lease or other disposition has been made will be the successor to the Company and shall succeed to, and be substituted for, and may exercise every right and power of, the Company under
this Indenture, and the Company, except in the case of a lease, shall be released from the obligation to pay the principal of and interest on the Notes.” 

u)    Section 6.01 of the Indenture is hereby amended and restated in its entirety as follows: 

“SECTION 6.01    Events of Default 

Each of the following is an “Event of Default”: 

(1)    default for 30 days in the payment when due of interest and Additional Interest, if any, on the Notes; 

(2)     default in the payment when due (at maturity, upon redemption or otherwise) of the principal of, or premium, if
any, on the Notes; 

  
 4 













 (3)     failure by the Company or any of the Restricted Subsidiaries to
comply with Article 5; 
 (4)    failure by the Company or any of the Restricted Subsidiaries to comply with any of the
other agreements in this Indenture (other than a failure that is the subject of clause (1) or (2)) for 60 days after receipt by the Issuers of written notice of such failure from the Trustee (or receipt by the Issuers and the Trustee of written
notice of such failure from the Holders of at least 25% in aggregate principal amount of the Notes then outstanding voting as a single class); 

(5)     [INTENTIONALLY OMITTED]; 

(6)     [INTENTIONALLY OMITTED]; 

(7)     the Company: 

(A) commences a voluntary insolvency proceeding, 

(B) consents to the entry of an order for relief against it in an involuntary insolvency proceeding, 

(C) consents to the appointment of a Bankruptcy Custodian of it or for all or substantially all of its property, 

(D) makes a general assignment for the benefit of its creditors, or 

(E) generally is not paying its debts as they become due; 

provided, however, that the liquidation of any Restricted Subsidiary into another Restricted Subsidiary, other than as part of a credit
reorganization, shall not constitute an Event of Default under this Section 6.01(7); 
 (8)     a court of
competent jurisdiction enters an order or decree under any Bankruptcy Law that: 
 (A) is for relief against the Company in an involuntary
insolvency proceeding; 
 (B) appoints a Bankruptcy Custodian of the Company for all or substantially all of the property of the Company; or

 (C) orders the liquidation of the Company; 

and the order or decree remains unstayed and in effect for 60 consecutive days; and 

(9)     [INTENTIONALLY OMITTED]” 

SECTION 2.02.    AMENDMENTS TO CERTAIN
DEFINITIONS. Subject to Section 4.02 hereof, Section 1.01 of the Indenture is hereby amended by deleting those definitions which appear solely in the text deleted
from the Indenture pursuant to the amendments contained in Section 2.01 herein. All cross-references in the Indenture to sections and clauses deleted by this Article II shall also be deleted in their entirety. 

  
 5 













 ARTICLE III 

AMENDMENTS TO THE NOTES 

The Notes include certain of the foregoing provisions from the Indenture to be deleted or amended pursuant to Article II hereof. Upon
the Operative Date, such provisions from the Notes shall be deemed deleted or amended as applicable. 
 ARTICLE IV 

MISCELLANEOUS PROVISIONS 

SECTION 4.01.    EFFECT OF SUPPLEMENTAL
INDENTURE. Except as amended hereby, all of the terms of the Indenture shall remain and continue in full force and effect and are hereby confirmed in all respects. From and after the date of this Supplemental
Indenture, all references to the Indenture (whether in the Indenture or in any other agreements, documents or instruments) shall be deemed to be references to the Indenture as amended and supplemented by this Supplemental Indenture. 

SECTION 4.02.    EFFECTIVENESS. This Supplemental Indenture shall become
effective and binding on the Issuers, the Guarantors, the Trustee and every Holder of the Notes heretofore or hereafter authenticated and delivered under the Indenture, upon the execution and delivery by the parties to this Supplemental Indenture;
provided that the amendments to the Indenture and the Notes set forth in Article II and Article III hereof shall not become operative until the Operative Date. Prior to the Operative Date, the Issuers or the Guarantors may terminate
this Supplemental Indenture upon written notice to the Trustee; provided that if the Exchange Offer has been terminated or withdrawn, or if upon the final settlement date of the Exchange Offer, the Exchange Notes Issuers have not issued the
Consideration, this Supplemental Indenture shall be automatically terminated and the Indenture will remain in effect in its current form. 

SECTION 4.03.    NEW YORK LAW TO
GOVERN; WAIVER OF JURY TRIAL. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. THE
ISSUERS, THE TRUSTEE AND EACH OF THE GUARANTORS CONSENTS AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY NEW YORK STATE OR U.S. FEDERAL COURT LOCATED IN THE BOROUGH OF MANHATTAN, CITY OF NEW YORK, COUNTY OF NEW YORK, STATE OF NEW YORK IN RELATION
TO ANY LEGAL ACTION OR PROCEEDING ARISING OUT OF, RELATING TO OR IN CONNECTION WITH THIS SUPPLEMENTAL INDENTURE AND ANY RELATED DOCUMENTS (UNLESS OTHERWISE PROVIDED IN ANY SUCH RELATED DOCUMENT). THE ISSUERS, THE TRUSTEE AND EACH OF THE GUARANTORS
WAIVES ANY OBJECTION TO PROCEEDINGS IN ANY SUCH COURTS, WHETHER ON THE GROUND OF VENUE OR ON THE GROUND THAT THE PROCEEDINGS HAVE BEEN BROUGHT IN AN INCONVENIENT FORUM. THE ISSUERS, THE TRUSTEE AND EACH OF THE GUARANTORS, TO THE EXTENT ORGANIZED
OUTSIDE OF THE UNITED STATES, SHALL APPOINT CT CORPORATION SYSTEM, 28 LIBERTY STREET, NEW YORK, NY 10005, AS ITS AGENT FOR SERVICE OF PROCESS IN ANY SUCH SUIT, ACTION OR PROCEEDING AND AGREES THAT SERVICE OF PROCESS UPON SAID AUTHORIZED AGENT SHALL
BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON IT IN ANY SUCH SUIT, ACTION OR PROCEEDING. THE ISSUERS, THE TRUSTEE AND EACH OF THE GUARANTORS AGREES TO DELIVER, UPON THE EXECUTION AND DELIVERY OF THIS SUPPLEMENTAL INDENTURE, A WRITTEN
ACCEPTANCE BY SUCH AGENT OF ITS APPOINTMENT AS SUCH AGENT. THE ISSUERS, THE TRUSTEE AND EACH OF THE GUARANTORS, TO THE EXTENT ORGANIZED OUTSIDE OF THE UNITED STATES, FURTHER AGREES TO TAKE ANY AND ALL ACTION, INCLUDING THE FILING OF ANY AND ALL SUCH
DOCUMENTS AND INSTRUMENTS, AS MAY BE REASONABLY NECESSARY TO CONTINUE SUCH DESIGNATION AND APPOINTMENT OF CT 

  
 6 













 
CORPORATION SYSTEM IN FULL FORCE AND EFFECT FOR SO LONG AS THE INDENTURE, REMAINS IN FORCE. THE ISSUERS, THE TRUSTEE AND EACH OF THE GUARANTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS SUPPLEMENTAL INDENTURE OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

SECTION 4.04.    COUNTERPARTS. The parties may sign any number of copies of this
Supplemental Indenture. Each signed copy (which may be provided via facsimile or other electronic transmission) shall be an original, but all of them together represent the same agreement. 

SECTION 4.05.    EFFECT OF HEADINGS. The Article
and Section headings herein are for convenience only and shall not affect the construction hereof. 

SECTION 4.06.    FURTHER ASSURANCES. The parties hereto will
execute and deliver such further instruments and do such further acts and things as may be reasonably required to carry out the intent and purpose of this Supplemental Indenture and the Indenture. 

SECTION 4.07.    THE TRUSTEE. The Trustee shall not be
responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein (other than with respect to the Trustee in the sixth recital contained
herein), all of such recitals are made solely by the Issuers and the Guarantors. 
 (Signature pages follow) 

  
 7 













 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed and attested, all as of the date first above written. 
  

					
	ISSUERS:
	
	ENDO DESIGNATED ACTIVITY COMPANY
		
	By:	 	 /s/ Deanna Voss

		 	Name:	 	Deanna Voss
		 	Title:	 	Secretary
	
	ENDO FINANCE LLC
		
	By:	 	 /s/ Deanna Voss

		 	Name:	 	Deanna Voss
		 	Title:	 	Secretary
	
	ENDO FINCO INC.
		
	By:	 	 /s/ Deanna Voss

		 	Name:	 	Deanna Voss
		 	Title:	 	Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO INTERNATIONAL PLC,
	    as a Guarantor
		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO LUXEMBOURG INTERNATIONAL FINANCING SARL
	    as a Guarantor
		
	By:	 	 /s/ Yoon Ah Oh

	Name:	 	Yoon Ah Oh
	Title:	 	A Manager
		
	By:	 	 /s/ Francois-Xavier Goossens

	Name:	 	Francois-Xavier Goossens
	Title:	 	B Manager



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO EUROFIN UNLIMITED COMPANY
	    as a Guarantor
		
	By:	 	 /s/ Marie-Therese Bolger

	Name:	 	Marie-Therese Bolger
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO AESTHETICS LLC
	    as a Guarantor
	by: ENDO HEALTH SOLUTIONS INC.,
	its managing member
		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO PROCUREMENT OPERATIONS LIMITED
	    as a Guarantor
		
	By:	 	 /s/ Rahul Garella

	Name:	 	Rahul Garella
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO GLOBAL DEVELOPMENT LIMITED
	    as a Guarantor
		
	By:	 	 /s/ Marie-Therese Bolger

	Name:	 	Marie-Therese Bolger
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO GLOBAL AESTHETICS LIMITED
	    as a Guarantor
		
	By:	 	 /s/ Rahul Garella

	Name:	 	Rahul Garella
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO GLOBAL BIOLOGICS LIMITED
	    as a Guarantor
		
	By:	 	 /s/ Rahul Garella

	Name:	 	Rahul Garella
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	OPERATIONS REFINANCING COMPANY BERMUDA LIMITED
	    as a Guarantor
		
	By:	 	 /s/ Mark T. Bradley

	Name:	 	Mark T. Bradley
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO U.S. FINANCE, LLC
	    as a Guarantor
	by: ENDO U.S. INC,
	its sole member
		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO INNOVATION VALERA, LLC
	    as a Guarantor
	by: ENDO PHARMACEUTICALS VALERA INC.,
	its managing member
		
	By:	 	 /s/ Terrell Stevens

	Name:	 	Terrell Stevens
	Title:	 	Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO GLOBAL FINANCE, LLC
	    as a Guarantor
		
	By:	 	 /s/ Mark T. Bradley

	Name:	 	Mark T. Bradley
	Title:	 	Manager



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ACTIENT THERAPEUTICS, LLC
	AUXILIUM PHARMACEUTICALS, LLC
	AUXILIUM INTERNATIONAL HOLDINGS, LLC
	DAVA PHARMACEUTICALS, LLC
	ENDO HEALTH SOLUTIONS INC.
	ENDO PHARMACEUTICALS INC.
	ENDO PHARMACEUTICALS SOLUTIONS INC.
	JHP GROUP HOLDINGS, LLC
	PAR, LLC
	SLATE PHARMACEUTICALS, LLC
	ENDO GENERICS HOLDINGS, INC.
	PAR STERILE PRODUCTS, LLC
	ANCHEN INCORPORATED
	ANCHEN PHARMACEUTICALS, INC.
	GENERICS INTERNATIONAL (US), INC.
	INNOTEQ, INC.
	PAR PHARMACEUTICAL COMPANIES, INC.
	PAR PHARMACEUTICAL HOLDINGS, INC.
	PAR PHARMACEUTICAL, INC.
	KALI LABORATORIES, LLC
	ASTORA WOMEN’S HEALTH, LLC
	  each, as a Guarantor
		
	By:	 	 /s/ Deanna
Voss                                        


	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ANCHEN 2 INCORPORATED
	ANCHEN PHARMACEUTICALS 2, INC.
	ENDO PHARMACEUTICALS VALERA INC.
	GENERICS INTERNATIONAL (US PARENT), INC.
	GENERICS INTERNATIONAL (US) 2, INC.
	INNOTEQ 2, INC.
	JHP GROUP HOLDINGS 2, INC.
	KALI LABORATORIES 2, INC.
	PAR PHARMACEUTICAL 2, INC.
	PAR TWO, INC.
	  each, as a Guarantor
		
	By:	 	 /s/ Terrell
Stevens                                        


	Name:	 	Terrell Stevens
	Title:	 	Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO PHARMACEUTICALS FINANCE LLC
	  as a Guarantor
	by: GENERICS INTERNATIONAL (US PARENT), INC.
	  its manager
		
	By:	 	 /s/ Terrell
Stevens                                        


	Name:	 	Terrell Stevens
	Title:	 	Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	JHP ACQUISITION, LLC
	as a Guarantor
	by: JHP GROUP HOLDINGS, LLC,
	its manager
		
	By:	 	 /s/ Deanna
Voss                                        


	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary
	
	ENDO LLC
	ENDO U.S. INC.
	ENDO FINANCE OPERATIONS LLC
	    each, as a Guarantor
		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Secretary
	
	GENERICS BIDCO I, LLC
	MOORES MILL PROPERTIES, L.L.C.
	VINTAGE PHARMACEUTICALS, LLC
	    each, as a Guarantor
	    by: GENERICS INTERNATIONAL (US), INC.,
	    its manager
		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	DAVA INTERNATIONAL, LLC
	    as a Guarantor
	    by: DAVA PHARMACEUTICALS, LLC,
	    its manager
		
	By:	 	 /s/ Deanna
Voss                                        


	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary
	
	ACTIENT PHARMACEUTICALS LLC
	    as a Guarantor
	    by: AUXILIUM PHARMACEUTICALS, LLC,
	    its manager
		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary
	
	AUXILIUM US HOLDINGS, LLC
	    as a Guarantor
	    by: AUXILIUM PHARMACEUTICALS, LLC,
	    its manager
		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	70 MAPLE AVENUE, LLC
	    as a Guarantor
	    by: ACTIENT PHARMACEUTICALS LLC,
	    its manager
	        by: AUXILIUM PHARMACEUTICALS, LLC,
	        its manager
		
	By:	 	 /s/ Deanna
Voss                                        


	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary
	
	TIMM MEDICAL HOLDINGS, LLC
	    as a Guarantor
	    by: ACTIENT PHARMACEUTICALS LLC,
	    its manager
	        by: AUXILIUM PHARMACEUTICALS, LLC,
	        its manager
		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary
	
	QUARTZ SPECIALTY PHARMACEUTICALS, LLC
	    as a Guarantor
	    by: GENERICS BIDCO I, LLC,
	    its manager
	        by: GENERICS INTERNATIONAL (US), INC.,
	               its manager
		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary
	
	ENDO PAR INNOVATION COMPANY, LLC
	    as a Guarantor
	    by: PAR PHARMACEUTICAL, INC.,
	    its manager
		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Assistant Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	 PAR LABORATORIES EUROPE, LTD.

    as a Guarantor

		
	By:	 	 /s/ Rahul
Garella                                        


	Name:	 	Rahul Garella
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	 ENDO SOMAR HOLDINGS B.V.

    as a Guarantor

		
	By:	 	 /s/ Rahul
Garella                                        


	Name:	 	Rahul Garella
	Title:	 	Managing Director A
		
	By:	 	 /s/ Gert Jan Rietberg

	Name:	 	Gert Jan Rietberg
	Title:	 	Managing Director B



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	 ENDO VENTURES CYPRUS LIMITED

    as a Guarantor

		
	By:	 	 /s/ Jenny
O’Connell                                       
 

	Name:	 	Jenny O’Connell
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	ENDO FINANCE UNLIMITED COMPANY
	 ENDO FINANCE II UNLIMITED COMPANY

ENDO FINANCE III UNLIMITED COMPANY
 ENDO FINANCE IV UNLIMITED
COMPANY
 ENDO FINANCE V UNLIMITED COMPANY
 ENDO IRELAND FINANCE
UNLIMITED COMPANY
 ENDO IRELAND FINANCE II LIMITED
 ENDO
MANAGEMENT LIMITED
 ENDO TOPFIN LIMITED
 ENDO VENTURES
LIMITED
 HAWK ACQUISITION IRELAND LIMITED
 ENDO IRELAND
HOLDINGS LIMITED
       each, as a Guarantor

		
	By:	 	 /s/ Rahul Garella

	Name:	 	Rahul Garella
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	 ENDO VENTURES BERMUDA LIMITED

    as a Guarantor

		
	By:	 	 /s/ Marie-Therese Bolger

	Name:	 	Marie-Therese Bolger
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	 ENDO GLOBAL VENTURES

    as a Guarantor

		
	By:	 	 /s/ Marie-Therese Bolger

	Name:	 	Marie-Therese Bolger
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	 ENDO BERMUDA FINANCE LIMITED

    as a Guarantor

		
	By:	 	 /s/ Rahul Garella

	Name:	 	Rahul Garella
	Title:	 	Director



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	PALADIN LABS CANADIAN HOLDING INC.
	 PALADIN LABS INC.

    each, as a Guarantor

		
	By:	 	 /s/ Deanna Voss

	Name:	 	Deanna Voss
	Title:	 	Secretary



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	 ENDO LUXEMBOURG HOLDING COMPANY S.À R.L.

    as a Guarantor

		
	By:	 	 /s/ Yoon Ah Oh

	Name:	 	Yoon Ah Oh
	Title:	 	A Manager
		
	By:	 	 /s/ François-Xavier Goossens

	Name:	 	François-Xavier Goossens
	Title:	 	B Manager
	
	 ENDO LUXEMBOURG FINANCE COMPANY I S.À R.L.

    as a Guarantor

		
	By:	 	 /s/ Yoon Ah Oh

	Name:	 	Yoon Ah Oh
	Title:	 	A Manager
		
	By:	 	 /s/ François-Xavier Goossens

	Name:	 	François-Xavier Goossens
	Title:	 	B Manager
	
	 ENDO LUXEMBOURG FINANCE COMPANY II S.À R.L.

    as a Guarantor

		
	By:	 	 /s/ Yoon Ah Oh

	Name:	 	Yoon Ah Oh
	Title:	 	A Manager
		
	By:	 	 /s/ François-Xavier Goossens

	Name:	 	François-Xavier Goossens
	Title:	 	B Manager



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	 ENDO US HOLDINGS LUXEMBOURG I S.À R.L.

    as a Guarantor

		
	By:	 	 /s/ Yoon Ah Oh

	Name:	 	Yoon Ah Oh
	Title:	 	A Manager
		
	By:	 	 /s/ François-Xavier Goossens

	Name:	 	François-Xavier Goossens
	Title:	 	B Manager



  
 [Signature Page to the
Supplemental Indenture] 













 
			
	 LUXEMBOURG ENDO SPECIALTY

PHARMACEUTICALS HOLDING I S.À R.L.

    as a Guarantor

		
	By:	 	 /s/ Yoon Ah Oh

	Name:	 	Yoon Ah Oh
	Title:	 	A Manager
		
	By:	 	 /s/ François-Xavier Goossens

	Name:	 	François-Xavier Goossens
	Title:	 	B Manager



  
 [Signature Page to
Supplemental Indenture] 













 
			
	 GENERICS INTERNATIONAL VENTURES ENTERPRISES LLC

    as Guarantor

	 by: ENDO VENTURES LIMITED,
 its sole
member

		
	By:	 	 /s/ Marie-Therese Bolger

	Name:	 	Marie-Therese Bolger
	Title:	 	Director



  
 [Signature Page to
Supplemental Indenture] 













 
			
	TRUSTEE:
	
	 WELLS FARGO BANK, NATIONAL ASSOCIATION,

    as Trustee

		
	By:	 	 /s/ Maddy Hughes

	Name:	 	Maddy Hughes
	Title:	 	Vice President



  
 [Signature Page to
Supplemental Indenture]